Jun 2026 (Q3 FY26) — Aug 4, 2026
Arrowhead Pharmaceuticals Q3 FY26 — Strong SHASTA Data and Accelerated sHTG Launch Plans
Read the full callArrowhead Pharmaceuticals (ARWR) earnings
- Jun 2026
- Jun 2026 (Q3 FY26)
- Sep 2025
Arrowhead Pharmaceuticals earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 75.3 | +171.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -226.0 | +370.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -194 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Guidance
What management said, and what became of it
14 of 16 judged targets kept · 21 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| PCSK9/APOC3 dimer clinical entry | Enter the clinic | Jun 2024 | Also in cardiometabolic, the ARO-DIMER-PA Phase I/IIa study in patients with mixed hyperlipidemia is nearing full enrollment, and we plan to share top line data in September. | Achieved |
| ARO-DIMER-PA interim data | Report interim data | Dec 2025 | the first clinical readout of ARO-DIMER-PA, the first dual functional siRNA candidate targeting both PCSK9 and APOC3 for LDL and TG lowering is expected in September. | On Track |
2 of ARROWHEAD PHARMACEUTICALS, INC.'s 37 targets were missed. See which ones, and which are quietly gone. The 2 above are the free sample; 35 more targets are in the full ledger.
Claimed
- REDEMPLO Phase III SHASTA-3 and SHASTA-4 studies met primary and all secondary endpoints, showing 79% and 81% median triglyceride reductions, respectively.
- Plozasiran demonstrated a 78% reduction in cumulative acute pancreatitis events in the broad sHTG population and 100% reduction in the highest risk subgroup.
- REDEMPLO prescription volume more than doubled quarter-on-quarter, with over 400 unique prescribers and strong payer coverage momentum.
- Acquired a Priority Review Voucher for $215 million to accelerate sNDA review for plozasiran in sHTG, aiming to shorten approval by 4 months.
- Pipeline advancements include positive ARO-INHBE Phase I data (44% liver fat reduction), full enrollment of Zodasiran Phase III, and upcoming data readouts for ARO-DIMER-PA and ARO-MAPT in September.
Qualified
Price
$58.5 +0.22% · +$0.13
Performance +62.7% 1Y
1Y: $35.96 on 14 Oct 2025 → $58.5. High $89.59 (4 Aug 2026), low $35.96 (14 Oct 2025).
- Previous close
- $58.37
- 52-week range
- $35.96 – $89.59
- One year
- +53.18%
Overview
- Symbol
- ARWR
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
14 of 16 judged targets kept · 21 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| PCSK9/APOC3 dimer clinical entry | Enter the clinic | Jun 2024 | Also in cardiometabolic, the ARO-DIMER-PA Phase I/IIa study in patients with mixed hyperlipidemia is nearing full enrollment, and we plan to share top line data in September. | Achieved |
| ARO-DIMER-PA interim data | Report interim data | Dec 2025 | the first clinical readout of ARO-DIMER-PA, the first dual functional siRNA candidate targeting both PCSK9 and APOC3 for LDL and TG lowering is expected in September. | On Track |
Claimed
- REDEMPLO Phase III SHASTA-3 and SHASTA-4 studies met primary and all secondary endpoints, showing 79% and 81% median triglyceride reductions, respectively.
- Plozasiran demonstrated a 78% reduction in cumulative acute pancreatitis events in the broad sHTG population and 100% reduction in the highest risk subgroup.
- REDEMPLO prescription volume more than doubled quarter-on-quarter, with over 400 unique prescribers and strong payer coverage momentum.
- Acquired a Priority Review Voucher for $215 million to accelerate sNDA review for plozasiran in sHTG, aiming to shorten approval by 4 months.
- Pipeline advancements include positive ARO-INHBE Phase I data (44% liver fat reduction), full enrollment of Zodasiran Phase III, and upcoming data readouts for ARO-DIMER-PA and ARO-MAPT in September.
Qualified
The full ledger
Open ARROWHEAD PHARMACEUTICALS, INC.’s full ledger
A free account opens 5 company ledgers a month. All 37 tracked commitments, with each call’s wording and source.
Call summaries
Every analysed call
Arrowhead Pharmaceuticals earnings calls (ARWR)
Financials
What the filings say
Net profit, year on year: −11% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 3 | 543 | 28 | 256 | 264 | 74 | 75 |
| Operating profit | -162 | -161 | 381 | -166 | 44 | 41 | -141 | -170 |
| Operating margin | — | −6456.5% | 70.2% | −596.2% | 17.2% | 15.5% | −191.6% | −226.0% |
| Other income | -11 | -14 | -12 | -14 | -8 | -13 | 4 | -9 |
| Interest | 15 | 22 | 22 | 24 | 22 | 23 | 24 | 25 |
| Profit before tax | -173 | -175 | 370 | -179 | 36 | 28 | -138 | -179 |
| Tax rate | −0.3% | −0.1% | 0.5% | 0.2% | 55.4% | 0.1% | −0.0% | −0.0% |
| Net profit | -171 | -173 | 370 | -175 | -24 | 31 | -133 | -194 |
| EPS ($ per share) | — | -1.39 | 2.78 | -1.26 | — | 0.22 | -0.93 | -1.36 |
| Line item | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -487 | -419 | -504 | -645 | -821 | -1,026 | -1,626 | -1,627 |
| Total liabilities | 16 | 106 | 61 | 301 | 274 | 478 | 949 | 882 |
| Fixed assets | 14 | 23 | 31 | 49 | 110 | 290 | 386 | 383 |
| Investments | — | — | 85 | 127 | 0 | — | — | 693 |
| Total assets | 112 | 350 | 523 | 710 | 692 | 766 | 1,140 | 1,385 |
| Line item | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -47 | 173 | -96 | 171 | -136 | -154 | -463 | 180 |
| Cash from investing | -7 | -48 | -241 | -142 | -5 | -96 | -420 | -129 |
| Cash from financing | 60 | 66 | 258 | 11 | 65 | 253 | 871 | 74 |
| Net cash flow | 5 | 192 | -78 | 41 | — | — | — | — |
| Capital expenditure | -1 | -12 | -12 | -24 | -53 | -177 | -141 | -23 |
| Free cash flow | -49 | 161 | -108 | 148 | -189 | -331 | -604 | 157 |
Insider filings
88 filings between Nov 28, 2025 and Aug 18, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$37.34M
64 sales by 10 insiders
69% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 12
- Award — granted as compensation
- 2
- Option exercise — converted options into shares
Also filed: 10 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Anzalone Christopher Richard | — | $24.01M | Jan 2, 2026 |
| Hamilton James C | — | $3.93M | Apr 23, 2026 |
| O'Brien Patrick | — | $3.12M | Jan 5, 2026 |
| PERRY MICHAEL S | — | $2.00M | Aug 18, 2026 |
| Ferrari Mauro | — | $1.02M | Dec 26, 2025 |
| Apel Daniel Joseph | — | $934.3K | Apr 22, 2026 |
| OLUKOTUN ADEOYE Y | — | $850.5K | Aug 18, 2026 |
| Vakiener Victoria | — | $679.5K | Dec 19, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 18, 2026 | PERRY MICHAEL S Director | Sale | 11,600 | $1.01M |
| Aug 18, 2026 | OLUKOTUN ADEOYE Y Director | Sale | 2,000 | $173.9K |
| Jun 15, 2026 | Cohen Matthew Gregory Director | Award | 11,882 | $0 |
| May 12, 2026 | Lu Hongbo Director | Sale 10b5-1 plan | 2,970 | $228.3K |
| Apr 23, 2026 | Hamilton James C Chief Medical Officer | Sale 10b5-1 plan | 10,000 | $750.0K |
| Apr 22, 2026 | Apel Daniel Joseph Chief Financial Officer | Sale 10b5-1 plan | 8,730 | $627.9K |
| Apr 22, 2026 | Apel Daniel Joseph Chief Financial Officer | Sale 10b5-1 plan | 3,208 | $224.9K |
| Apr 22, 2026 | Apel Daniel Joseph Chief Financial Officer | Sale 10b5-1 plan | 1,157 | $81.5K |
| Mar 5, 2026 | Hamilton James C Chief Medical Officer | Sale 10b5-1 plan | 10,000 | $641.9K |
| Jan 6, 2026 | O'Brien Patrick COO | Gift | 540 | $0 |
| Jan 6, 2026 | O'Brien Patrick COO | Gift | 440 | $0 |
| Jan 6, 2026 | O'Brien Patrick COO | Award | 75,000 | $0 |
| Jan 6, 2026 | Hamilton James C Chief Medical Officer | Award | 75,000 | $0 |
| Jan 6, 2026 | O'Brien Patrick COO | Gift | 540 | $0 |
| Jan 6, 2026 | Apel Daniel Joseph Chief Financial Officer | Award | 75,000 | $0 |
| Jan 6, 2026 | O'Brien Patrick COO | Gift | 540 | $0 |
| Jan 6, 2026 | O'Brien Patrick COO | Gift | 440 | $0 |
| Jan 5, 2026 | O'Brien Patrick COO | Sale 10b5-1 plan | 900 | $59.4K |
| Jan 5, 2026 | O'Brien Patrick COO | Sale 10b5-1 plan | 2,700 | $174.0K |
| Jan 5, 2026 | O'Brien Patrick COO | Sale 10b5-1 plan | 11,842 | $756.0K |
| Jan 5, 2026 | O'Brien Patrick COO | Sale 10b5-1 plan | 13,451 | $846.9K |
| Jan 5, 2026 | O'Brien Patrick COO | Sale 10b5-1 plan | 6,164 | $383.6K |
| Jan 5, 2026 | O'Brien Patrick COO | Sale 10b5-1 plan | 4,368 | $267.3K |
| Jan 5, 2026 | Hamilton James C Chief Medical Officer | Sale 10b5-1 plan | 309 | $21.0K |
| Jan 5, 2026 | Hamilton James C Chief Medical Officer | Sale 10b5-1 plan | 437 | $28.8K |
| Jan 5, 2026 | Hamilton James C Chief Medical Officer | Sale 10b5-1 plan | 1,200 | $77.4K |
| Jan 5, 2026 | Hamilton James C Chief Medical Officer | Sale 10b5-1 plan | 12,711 | $812.9K |
| Jan 5, 2026 | Hamilton James C Chief Medical Officer | Sale 10b5-1 plan | 14,792 | $932.0K |
| Jan 5, 2026 | Hamilton James C Chief Medical Officer | Sale 10b5-1 plan | 6,090 | $379.3K |
| Jan 5, 2026 | O'Brien Patrick COO | Sale 10b5-1 plan | 313 | $21.3K |
| Jan 5, 2026 | Hamilton James C Chief Medical Officer | Sale 10b5-1 plan | 4,625 | $283.2K |
| Jan 5, 2026 | O'Brien Patrick COO | Sale 10b5-1 plan | 46 | $3.1K |
| Jan 5, 2026 | O'Brien Patrick COO | Sale 10b5-1 plan | 2,336 | $149.6K |
| Jan 5, 2026 | O'Brien Patrick COO | Sale 10b5-1 plan | 5,873 | $369.5K |
| Jan 5, 2026 | O'Brien Patrick COO | Sale 10b5-1 plan | 900 | $56.0K |
| Jan 5, 2026 | O'Brien Patrick COO | Sale 10b5-1 plan | 600 | $36.7K |
| Jan 2, 2026 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 plan | 7,416 | $488.6K |
| Jan 2, 2026 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 plan | 5,771 | $383.1K |
| Dec 31, 2025 | O'Brien Patrick COO | Gift 10b5-1 plan | 560 | $0 |
| Dec 31, 2025 | O'Brien Patrick COO | Gift 10b5-1 plan | 560 | $0 |
| Dec 31, 2025 | O'Brien Patrick COO | Gift 10b5-1 plan | 560 | $0 |
| Dec 31, 2025 | O'Brien Patrick COO | Gift 10b5-1 plan | 560 | $0 |
| Dec 31, 2025 | O'Brien Patrick COO | Gift 10b5-1 plan | 560 | $0 |
| Dec 29, 2025 | Anzalone Christopher Richard Chief Executive Officer | Option exercise 10b5-1 plan | 35,181 | $216.4K |
| Dec 29, 2025 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 plan | 16,545 | $1.14M |
| Dec 29, 2025 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 plan | 35,181 | $2.44M |
| Dec 29, 2025 | Anzalone Christopher Richard Chief Executive Officer | Option exercise 10b5-1 plan | 16,545 | $101.8K |
| Dec 26, 2025 | Ferrari Mauro Director | Sale 10b5-1 plan | 7,530 | $527.1K |
| Dec 22, 2025 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 plan | 10,012 | $684.1K |
| Dec 22, 2025 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 plan | 2,574 | $177.2K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ARROWHEAD PHARMACEUTICALS, INC.
Free account. Everything above stays public.
Write why you follow ARROWHEAD PHARMACEUTICALS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading